Prognose des europäischen Marktes für Pharmakokinetikdienstleistungen bis 2031 – Regionale Analyse – nach Arzneimitteltyp (kleine Moleküle, große Moleküle und Impfstoffe), Servicetyp (präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalyse und andere), therapeutische Anwendung (Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere) und Endbenutzer (Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere)
Das Outsourcing von Pharmakokinetik-Dienstleistungen an CROs treibt den europäischen Markt für Pharmakokinetik-Dienstleistungen an
Das Outsourcing von Pharmakokinetik-Dienstleistungen an Auftragsforschungsinstitute (CROs) bietet Arzneimittelherstellern und -sponsoren mehrere Vorteile. Durch die Wahl dieser Dienstleistungen können sie kosteneffizient arbeiten. Darüber hinaus können sie sich darauf konzentrieren, flexibel zu arbeiten und Skalierbarkeit in ihre Kerngeschäfte zu bringen, während sie gleichzeitig schnelle Durchlaufzeiten erreichen. Outsourcing hilft Pharmaunternehmen, sich auf die Produktkommerzialisierung zu konzentrieren und gleichzeitig Maßnahmen zum Kapazitätsaufbau, zur Kostensenkung und zum Datenmanagement umzusetzen. Der Prozess der Arzneimittelentdeckung ist komplex und jeder Fehler oder jedes falsche Ergebnis kann zu erheblichen Kosten führen und den Prozess verzögern. CROs beschäftigen erfahrene Wissenschaftler und Forscher, die über Fachwissen in Pharmakokinetik und anderen Bereichen verfügen. Auf diese Weise bieten sie Pharmaunternehmen Zugang zu ihrem Fachwissen, wodurch die Notwendigkeit entfällt, in die Einstellung solcher qualifizierten Arbeitskräfte zu investieren oder zusätzliche Schulungen für deren Aufbau anzubieten. Daher entscheiden sich kleine Unternehmen mit vielversprechenden Arzneimittelkandidaten, aber begrenzten Ressourcen und große Unternehmen, die ihre Geschäftstätigkeit diversifizieren möchten, für klinische Forschungsdienstleistungen, die von gut organisierten CROs erbracht werden, was den europäischen Markt für Pharmakokinetikdienstleistungen stärkt.
Überblick über den europäischen Markt für Pharmakokinetikdienstleistungen
Der europäische Markt für Pharmakokinetikdienstleistungen ist in Deutschland, Frankreich, Großbritannien, Spanien, Italien und das übrige Europa unterteilt. Länder wie Deutschland und Italien werden voraussichtlich einen erheblichen Marktanteil in der Region haben, und Länder wie Frankreich, Großbritannien und Spanien werden wahrscheinlich Wachstumschancen für Pharmakokinetikdienstleistungen bieten. Der europäische Markt für Pharmakokinetikdienstleistungen dürfte in den kommenden Jahren mit der steigenden Zahl klinischer Studien zur Entwicklung neuer Medikamente und der zunehmenden Einführung von In-vivo- und In-vitro-Modellen zum Verständnis der Variabilität der Pharmakokinetik wachsen.
Umsatz und Prognose des europäischen Marktes für Pharmakokinetikdienstleistungen bis 2031 (Mio. USD)
Segmentierung des europäischen Marktes für Pharmakokinetikdienstleistungen
Der europäische Markt für Pharmakokinetikdienstleistungen ist nach Medikamententyp, Servicetyp, therapeutischer Anwendung, Endnutzer und Land kategorisiert.
Basierend auf dem Medikamententyp ist der europäische Markt für Pharmakokinetikdienstleistungen in kleine Moleküle, große Moleküle und Impfstoffe segmentiert. Das Segment der kleinen Moleküle hatte 2023 den größten Marktanteil.
In Bezug auf den Servicetyp ist der europäische Markt für Pharmakokinetikdienstleistungen in präklinische ADME- und Humanstudien, PK/PD-Analyse und -Berichterstattung, Dosierungssimulationen, Risikoanalyse und andere unterteilt. Das Segment präklinische ADME und Humanstudien hatte 2023 den größten Marktanteil.
Nach therapeutischer Anwendung ist der europäische Markt für Pharmakokinetikdienstleistungen in Onkologie, Infektionskrankheiten, neurologische Erkrankungen, Autoimmunerkrankungen, gynäkologische Erkrankungen, Herz-Kreislauf-Erkrankungen, Atemwegserkrankungen und andere unterteilt. Das Segment Onkologie hatte 2023 den größten Marktanteil.
Nach Endnutzer ist der europäische Markt für Pharmakokinetikdienstleistungen in Pharma- und Biotechnologieunternehmen, Auftragsforschungsinstitute und andere unterteilt. Das Segment Auftragsforschungsinstitute hatte 2023 den größten Marktanteil.
Nach Ländern ist der europäische Markt für Pharmakokinetikdienstleistungen in Deutschland, Frankreich, Großbritannien, Italien, Spanien und das übrige Europa unterteilt. Frankreich dominierte 2023 den Marktanteil der europäischen Pharmakokinetikdienstleistungen.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc., Allucent, PACIFIC BIOLABS und SGS SA sind einige der führenden Unternehmen auf dem europäischen Markt für Pharmakokinetikdienstleistungen.
TABLE OF CONTENTS
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Europe Pharmacokinetics Services Market - Key Market Dynamics
4.1 Market Drivers
4.1.1 Rising Prevalence of Chronic and Infectious Diseases
4.1.2 Expanding Range of Application of Pharmacokinetic Studies
4.1.3 Outsourcing of Pharmacokinetics Services to CROs
4.2 Market Restraints
4.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
4.3 Market Opportunities
4.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
4.4 Future Trend
4.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
4.5 Impact of Drivers and Restraints:
5. Pharmacokinetics Services Market - Europe Analysis
5.1 Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
6. Europe Pharmacokinetics Services Market Analysis - by Drug Type
6.1 Overview
6.2 Small Molecule
6.2.1 Overview
6.2.2 Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.3 Large Molecule
6.3.1 Overview
6.3.2 Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
6.4 Vaccines
6.4.1 Overview
6.4.2 Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7. Europe Pharmacokinetics Services Market Analysis - by Service Type
7.1 Overview
7.2 Pre-Clinical ADME and Human Studies
7.2.1 Overview
7.2.2 Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.3 PK/PD Analysis and Reporting
7.3.1 Overview
7.3.2 PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.4 Dosing Simulations
7.4.1 Overview
7.4.2 Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.5 Risk Analysis
7.5.1 Overview
7.5.2 Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. Europe Pharmacokinetics Services Market Analysis - by Therapeutic Application
8.1 Oncology
8.1.1 Overview
8.1.2 Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.2 Infectious Diseases
8.2.1 Overview
8.2.2 Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.3 Neurological Disorders
8.3.1 Overview
8.3.2 Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.4 Autoimmune Diseases
8.4.1 Overview
8.4.2 Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.5 Gynecological Disorders
8.5.1 Overview
8.5.2 Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.6 Cardiovascular Diseases
8.6.1 Overview
8.6.2 Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.7 Respiratory Disorders
8.7.1 Overview
8.7.2 Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8.8 Others
8.8.1 Overview
8.8.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. Europe Pharmacokinetics Services Market Analysis - by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.2 Contract Research Organization
9.2.1 Overview
9.2.2 Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. Europe Pharmacokinetics Services Market - Country Analysis
10.1 Europe
10.1.1 Europe Pharmacokinetics Services Market Breakdown by Countries, 2023 and 2031 (%)
10.1.1.1 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.1.3 Germany: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.1.4 Germany: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.1.5 Germany: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.1.6 Germany: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.2.3 France: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.2.4 France: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.2.5 France: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.2.6 France: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.3 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.3.3 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.3.4 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.3.5 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.3.6 United Kingdom: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.4 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.4.3 Italy: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.4.4 Italy: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.4.5 Italy: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.4.6 Italy: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.5 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.5.3 Spain: Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.5.4 Spain: Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.5.5 Spain: Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.5.6 Spain: Europe Pharmacokinetics Services Market Breakdown, by End User
10.1.1.6 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10.1.1.6.3 Rest of Europe Pharmacokinetics Services Market Breakdown, by Drug Type
10.1.1.6.4 Rest of Europe Pharmacokinetics Services Market Breakdown, by Service Type
10.1.1.6.5 Rest of Europe Pharmacokinetics Services Market Breakdown, by Therapeutic Application
10.1.1.6.6 Rest of Europe Pharmacokinetics Services Market Breakdown, by End User
11. Company Profile
11.1 Charles River Laboratories International Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eurofins Scientific SE
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Evotec SE
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Certara Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.5 Parexel International Corp
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Thermo Fisher Scientific Inc.
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Allucent
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 PACIFIC BIOLABS
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 SGS SA
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
12. Appendix
12.1 About The Insight Partners
12.2 Glossary of Terms for Pharmacokinetic Services Market
?
List of Tables
Table 1. Europe Pharmacokinetics Services Market Segmentation
Table 2. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 3. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 4. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 5. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 6. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 7. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 8. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 9. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 10. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 11. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 12. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 13. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 14. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 15. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 16. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 17. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 18. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 19. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 20. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 21. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 22. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Drug Type
Table 23. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Service Type
Table 24. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by Therapeutic Application
Table 25. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million) - by End User
Table 26. Glossary of Terms
?
List of Figures
Figure 1. Europe Pharmacokinetics Services Market Segmentation, by Country
Figure 2. Europe Pharmacokinetics Services Market - Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Europe Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
Figure 5. Europe Pharmacokinetics Services Market Share (%) - by Drug Type (2023 and 2031)
Figure 6. Small Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 7. Large Molecule: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 8. Vaccines: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 9. Europe Pharmacokinetics Services Market Share (%) - by Service Type (2023 and 2031)
Figure 10. Pre-Clinical ADME and Human Studies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 11. PK/PD Analysis and Reporting: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 12. Dosing Simulations: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 13. Risk Analysis: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 14. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 15. Europe Pharmacokinetics Services Market Share (%) - by Therapeutic Application (2023 and 2031)
Figure 16. Oncology: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 17. Infectious Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 18. Neurological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 19. Autoimmune Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 20. Gynecological Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 21. Cardiovascular Diseases: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 22. Respiratory Disorders: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 23. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 24. Europe Pharmacokinetics Services Market Share (%) - by End User (2023 and 2031)
Figure 25. Pharmaceutical and Biotechnology Companies: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 26. Contract Research Organization: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 27. Others: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 28. Europe Pharmacokinetics Services Market - Revenue by Key Countries Revenue 2023 (US$ Million)
Figure 29. Europe Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 30. Germany: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 31. France: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 32. United Kingdom: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 33. Italy: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 34. Spain: Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
Figure 35. Rest of Europe Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- Allucent
- Certara Inc.
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- PACIFIC BIOLABS
- Parexel International Corp
- SGS SA
- Thermo Fisher Scientific Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe pharmacokinetics services market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the Europe pharmacokinetics services market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the Europe pharmacokinetics services market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.